SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotechnology & Drugs
An SI Board Since February 2001
Posts SubjectMarks Bans
232 7 0
Emcee:  2MAR$ Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
32ADRX ( $64-$67) profits rise on drug distribution unit FT. LAUDERDALE, Fla., Ju2MAR$-7/28/2001
31CRA ($31) Celera loss widens, Applied Biosystems profit falls By Toni Clarke NE2MAR$-7/28/2001
30AMGN ( $57-$61) second-quarter earnings rise 6 percent, upgrade By Deena Beasle2MAR$-7/28/2001
29VRTX ( $41-$43) Q2 loss of 16 cents CAMBRIDGE, Mass., July 26 (Reuters) - Drug2MAR$-7/27/2001
28ICOS ($60-$63-$61) posts narrower second quarter loss BOTHELL, Wash., July 26 (2MAR$-7/27/2001
27GILD ($54-$51 $54) Q2 loss is wider than expected -$34c vs -$24 FOSTER CITY, Ca2MAR$-7/27/2001
26HGSI ( $51-55-53) loss increases; revenue flat By Ted Griffith, CBS.MarketWatc2MAR$-7/27/2001
25BMET $51 (split-aug) profits rise, helped by aging baby boomers, 15 consecutive 2MAR$-7/27/2001
24CELG ($24-$27) Beats Revenue Estimates, But Falls Short on EPS 10:09 AM EST, J2MAR$-7/26/2001
23ABGX ( $26-$28)loss wider than expected By Ted Griffith, CBS.MarketWatch.com La2MAR$-7/25/2001
22MLNM ( $31-$33-$32) 2001 loss from operations NEW YORK, July 18 (Reuters) - Mil2MAR$-7/19/2001
21Biotech drug sales the focus for Q2 earnings By Deena Beasley LOS ANGEL2MAR$-7/8/2001
20<b>The Drug Sector's Drug Problem</b> thestreet.com Investor op2MAR$-7/5/2001
19Before The Bell - BGEN down ( $ 54), futures rise (Recasts lead in include Dim2MAR$-6/25/2001
18DJ Icos Corp Files $300M Mixed Securities Shelf >ICOS WASHINGTON (Dow Jones)-2MAR$-6/25/2001
17Merck ($74 sell-->$67) Lowers Profit Estimate, Biotechs slide By Jed Seltze2MAR$-6/23/2001
16BGEN ($65 sold--> $59) Spends the Day on the Defensive By Adam Feuerstein S2MAR$-6/23/2001
152MAR$, Other stem cell stocks to keep an eye on are CCEL and DCRN. They both werronayre-6/7/2001
14PDLI ( $56 ...?) Profits Top Forecasts NEW YORK (Reuters) - Biotechnology comp2MAR$-5/14/2001
13MYGN ( $60 sell $55)quarterly loss narrows (UPDATE: adds details, company commen2MAR$-5/14/2001
12Hi 2MAR$, a little more to ponder along those lines... U-M Health System's ronayre-5/12/2001
11U.S. approves Novartis cancer drug Gleevec (adds details, fresh quotes; upd2MAR$-5/10/2001
10MEDX ($24) $4c vs $3c PRINCETON, N.J., May 8 /PRNewswire/ -- Medarex, Inc. (2MAR$-5/9/2001
9CEPH ($61 unchanged)loss narrows on strong sales growth NEW YORK, May 8 (Reuters2MAR$-5/9/2001
8CRA ($35 up $38) biotech stocks gain ground By Ted Griffith, CBS.MarketWatch.c2MAR$-4/29/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News